GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
GSK price target raised to 1,500 GBp from 1,440 GBp at JPMorgan
JPMorgan raised the firm’s price target on GSK (GSK) to 1,500 GBp from 1,440 GBp and keeps an Underweight rating on the shares.Maximize Your ...
GSK LAWSUIT ALERT: Levi & Korsinsky Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...
FiercePharma2d
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once again. GSK now expects to generate more than 40 billion pound ...
The Financial Times3d
GSK launches £2bn buyback on strong HIV and cancer drugs sales
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of ...
FierceBiotech12d
GSK offers up to £50M to conduct cancer vaccine research with the University of Oxford
British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work with the University of Oxford on a cancer vaccine research program.
London Evening Standard3d
GSK lifts long-term sales targets on new drug pipeline
It came as the boss of the London-listed firm cheered an ‘excellent’ performance in 2024. GSK has increased its long-term sales guidance amid hopes for a boost from new speciality medicines ...
The Motley Fool UK2d
The GSK share price jumps 6% on positive FY 2024 results. Is it a stock to consider now?
Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results. When investing, your capital is at risk. The value of your ...
Fortune24d
British pharma giant GSK to acquire U.S. drug developer IDRx in $1.15 billion deal
© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...
STAT3d
This week in biotech earnings so far
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Let’s get into all the earnings and political news ...
Yahoo Finance26d
GSK Enters Agreement to Acquire IDRx, Inc.
January 13, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...
FierceBiotech26d
JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care
In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset. “We really became impressed with what IDRx had achieved ...